Abstract
Nivolumab belongs to the class of check point blockers that showed enormous potential in the treatment of melanoma. Its use as a monotherapy was approved by US FDA for the treatment of metastatic melanoma in December 2014 and its combination with ipilimumab was approved in September 2015. Nivolumab is a monoclonal antibody against the PD-1 receptor. PD-1 belongs to the immunoglobulin superfamily of proteins and is expressed on the cell surface of T- and B-cells in response to inflammatory signals in the tumor microenvironment. Upon binding with its ligands, PD-L1 (B7-H1) or PD-L2 (B7-DC), it generates a ‘negative’ signal inside T-cells and results in inhibition of T-cell functions. The current chapter describes the PD-1 receptors and the clinical potential of PD-1 blocker nivolumab. In the introduction section of the chapter, the discovery of PD-1 receptors and the phenotype of PD-1 deficient mice (Pdcd −/− mice) are described. Next, the structure of PD-1 receptor, its biology and the signaling events that follow the activation of PD-1 receptor are explained. After giving a brief description of Opdivo, the marketed formulation of nivolumab, its clinical pharmacology and mechanism of action at cellular level is described. The details of clinical trials that tested the use of nivolumab in melanoma patients and the adverse effects, drug interactions as well as contraindications of nivolumab are then discussed. In the end, the limitations of using nivolumab are described.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010). The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews, 236, 219–242. doi:10.1111/j.1600-065X.2010.00923.x IMR923 [pii].
Yao, S., Zhu, Y., & Chen, L. (2013). Advances in targeting cell surface signalling molecules for immune modulation. Nature Reviews Drug Discovery, 12(2), 130–146. doi:10.1038/nrd3877 nrd3877 [pii].
Intlekofer, A. M., & Thompson, C. B. (2013). At the bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. Journal of Leukocyte Biology, 94(1), 25–39. doi:10.1189/jlb.1212621 jlb.1212621 [pii].
Weber, J. (2010). Immune checkpoint proteins: A new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockade. Seminars in Oncology, 37(5), 430–439. doi:10.1053/j.seminoncol.2010.09.005. S0093-7754(10)00159-4 [pii].
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO Journal, 11(11), 3887–3895.
Okazaki, T., Iwai, Y., & Honjo, T. (2002). New regulatory co-receptors: Inducible co-stimulator and PD-1. Current Opinion in Immunology, 14(6), 779–782. S0952791502003989 [pii].
Okazaki, T., & Honjo, T. (2007). PD-1 and PD-1 ligands: From discovery to clinical application. International Immunology, 19(7), 813–824. doi:10.1093/intimm/dxm057 dxm057 [pii].
Shinohara, T., Taniwaki, M., Ishida, Y., Kawaichi, M., & Honjo, T. (1994). Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics, 23(3), 704–706. doi:10.1006/geno.1994.1562. S0888-7543(84)71562-X [pii].
Nishimura, H., Minato, N., Nakano, T., & Honjo, T. (1998). Immunological studies on PD-1 deficient mice: Implication of PD-1 as a negative regulator for B cell responses. International Immunology, 10(10), 1563–1572.
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999). Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity, 11(2), 141–151. S1074-7613(00)80089-8 [pii].
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., et al. (2001). Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science, 291(5502), 319–322. doi:10.1126/science.291.5502.319 291/5502/319 [pii].
Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., et al. (2003). Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nature Medicine, 9(12), 1477–1483. doi:10.1038/nm955 nm955 [pii].
Wang, J., Yoshida, T., Nakaki, F., Hiai, H., Okazaki, T., & Honjo, T. (2005). Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. Proceedings of the National Academy of Sciences of the United States of America, 102(33), 11823–11828. doi:10.1073/pnas.0505497102 0505497102 [pii].
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. Journal of Experimental Medicine, 192(7), 1027–1034.
Carter, L., Fouser, L. A., Jussif, J., Fitz, L., Deng, B., Wood, C. R., et al. (2002). PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. European Journal of Immunology, 32(3), 634–643. doi:10.1002/1521-4141(200203)32:3<634:AID-IMMU634>3.0.CO;2-9 [pii] 10.1002/1521-4141(200203)32:3<634:AID-IMMU634>3.0.CO;2-9.
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., et al. (2006). Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 439(7077), 682–687. doi:10.1038/nature04444 nature04444 [pii].
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., et al. (2006). PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 443(7109), 350–354. doi:10.1038/nature05115 nature05115 [pii].
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., et al. (2009). Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 114(8), 1537–1544. doi:10.1182/blood-2008-12-195792 blood-2008-12-195792 [pii].
Zou, W., & Chen, L. (2008). Inhibitory B7-family molecules in the tumour microenvironment. Nature Reviews Immunology, 8(6), 467–477. doi:10.1038/nri2326 nri2326 [pii].
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Medicine, 8(8), 793–800. doi:10.1038/nm730 nm730 [pii].
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., et al. (2004). Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 101(49), 17174–17179. doi:10.1073/pnas.0406351101 0406351101 [pii].
Dorfman, D. M., Brown, J. A., Shahsafaei, A., & Freeman, G. J. (2006). Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. American Journal of Surgical Pathology, 30(7), 802–810. doi:10.1097/01.pas.0000209855.28282.ce 00000478-200607000-00003 [pii].
Liu, J., Hamrouni, A., Wolowiec, D., Coiteux, V., Kuliczkowski, K., Hetuin, D., et al. (2007). Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood, 110(1), 296–304. doi:10.1182/blood-2006-10-051482 blood-2006-10-051482 [pii].
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002). Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proceedings of the National Academy of Sciences of the United States of America, 99(19), 12293–12297. doi:10.1073/pnas.192461099 192461099 [pii].
Ishida, M., Iwai, Y., Tanaka, Y., Okazaki, T., Freeman, G. J., Minato, N., et al. (2002). Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunology Letters, 84(1), 57–62. S0165247802001426 [pii].
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., et al. (2005). Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Research, 65(3), 1089–1096 65/3/1089 [pii].
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Desbois, M., Delahaye, N., et al. (2011). IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Research, 71(16), 5393–5399. doi:10.1158/0008-5472.CAN-11-0993 0008-5472.CAN-11-0993 [pii].
Rotte, A., Bhandaru, M., Zhou, Y., & McElwee, K. J. (2015). Immunotherapy of melanoma: Present options and future promises. Cancer and Metastasis Reviews, 34(1), 115–128. doi:10.1007/s10555-014-9542-0.
FDA approves Keytruda for advanced melanoma. (2014, September 4). FDA News Release.
FDA approves Opdivo for advanced melanoma. (2014, December 22). FDA News Release.
Nivolumab in combination with ipilimumab. (2015, September 30). FDA Approved drugs database.
Homet Moreno, B., Parisi, G., Robert, L., & Ribas, A. (2015). Anti-PD-1 therapy in melanoma. Seminars in Oncology, 42(3), 466–473. doi:10.1053/j.seminoncol.2015.02.008 S0093-7754(15)00024-X [pii].
Zhang, X., Schwartz, J. C., Guo, X., Bhatia, S., Cao, E., Lorenz, M., et al. (2004). Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity, 20(3), 337–347. S1074761304000512 [pii].
Stamper, C. C., Zhang, Y., Tobin, J. F., Erbe, D. V., Ikemizu, S., Davis, S. J., et al. (2001). Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature, 410(6828), 608–611. doi:10.1038/35069118 35069118 [pii].
Long, E. O. (1999). Regulation of immune responses through inhibitory receptors. Annual Review of Immunology, 17, 875–904. doi:10.1146/annurev.immunol.17.1.875.
Riley, J. L. (2009). PD-1 signaling in primary T cells. Immunological Reviews, 229(1), 114–125. doi:10.1111/j.1600-065X.2009.00767.x IMR767 [pii].
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008). PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology, 26, 677–704. doi:10.1146/annurev.immunol.26.021607.090331.
Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001). PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proceedings of the National Academy of Sciences of the United States of America, 98(24), 13866–13871. doi:10.1073/pnas.231486598 231486598 [pii].
Dariavach, P., Mattei, M. G., Golstein, P., & Lefranc, M. P. (1988). Human Ig superfamily CTLA-4 gene: Chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains. European Journal of Immunology, 18(12), 1901–1905. doi:10.1002/eji.1830181206.
Nielsen, C., Ohm-Laursen, L., Barington, T., Husby, S., & Lillevang, S. T. (2005). Alternative splice variants of the human PD-1 gene. Cellular Immunology, 235(2), 109–116. doi:10.1016/j.cellimm.2005.07.007. S0008-8749(05)00174-7 [pii].
Wan, B., Nie, H., Liu, A., Feng, G., He, D., Xu, R., et al. (2006). Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. The Journal of Immunology, 177(12), 8844–8850. 177/12/8844 [pii].
Pentcheva-Hoang, T., Chen, L., Pardoll, D. M., & Allison, J. P. (2007). Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proceedings of the National Academy of Sciences of the United States of America, 104(45), 17765–17770. doi:10.1073/pnas.0708767104 0708767104 [pii].
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., et al. (2005). CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Molecular and Cellular Biology, 25(21), 9543–9553. doi:10.1128/MCB.25.21.9543-9553.2005 25/21/9543 [pii].
Sheppard, K. A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., et al. (2004). PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Letters, 574(1–3), 37–41. doi:10.1016/j.febslet.2004.07.083 S0014579304009779 [pii].
Okazaki, T., & Honjo, T. (2006). The PD-1-PD-L pathway in immunological tolerance. Trends in Immunology, 27(4), 195–201. doi:10.1016/j.it.2006.02.001. S1471-4906(06)00048-2 [pii].
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004). SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. The Journal of Immunology, 173(2), 945–954.
Frauwirth, K. A., Riley, J. L., Harris, M. H., Parry, R. V., Rathmell, J. C., Plas, D. R., et al. (2002). The CD28 signaling pathway regulates glucose metabolism. Immunity, 16(6), 769–777. S1074761302003230 [pii].
Malek, T. R., & Castro, I. (2010). Interleukin-2 receptor signaling: At the interface between tolerance and immunity. Immunity, 33(2), 153–165. doi:10.1016/j.immuni.2010.08.004 S1074-7613(10)00287-6 [pii].
Blair, P. J., Riley, J. L., Levine, B. L., Lee, K. P., Craighead, N., Francomano, T., et al. (1998). CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction. The Journal of Immunology, 160(1), 12–15.
Nurieva, R., Thomas, S., Nguyen, T., Martin-Orozco, N., Wang, Y., Kaja, M. K., et al. (2006). T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO Journal, 25(11), 2623–2633. doi:10.1038/sj.emboj.7601146 7601146 [pii].
Saunders, P. A., Hendrycks, V. R., Lidinsky, W. A., & Woods, M. L. (2005). PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion. European Journal of Immunology, 35(12), 3561–3569. doi:10.1002/eji.200526347.
Bennett, F., Luxenberg, D., Ling, V., Wang, I. M., Marquette, K., Lowe, D., et al. (2003). Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: Attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. The Journal of Immunology, 170(2), 711–718.
Riley, J. L., Mao, M., Kobayashi, S., Biery, M., Burchard, J., Cavet, G., et al. (2002). Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proceedings of the National Academy of Sciences of the United States of America, 99(18), 11790–11795. doi:10.1073/pnas.162359999 162359999 [pii].
Opdivo package insert. Product information: Bristol-Myers Squibb.
McDermott, D. F., & Atkins, M. B. (2013). PD-1 as a potential target in cancer therapy. Cancer Med, 2(5), 662–673. doi:10.1002/cam4.106.
Linsley, P. S., Bradshaw, J., Greene, J., Peach, R., Bennett, K. L., & Mittler, R. S. (1996). Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity, 4(6), 535–543. S1074-7613(00)80480-X [pii].
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012). Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Current Opinion in Immunology, 24(2), 207–212. doi:10.1016/j.coi.2011.12.009 S0952-7915(11)00184-1 [pii].
Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., et al. (2003). Expression of the B7-related molecule B7-H1 by glioma cells: A potential mechanism of immune paralysis. Cancer Research, 63(21), 7462–7467.
Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., et al. (2003). B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Research, 63(19), 6501–6505.
Wu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X. G., & Xu, N. (2006). Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochemica, 108(1), 19–24. doi:10.1016/j.acthis.2006.01.003 S0065-1281(06)00014-6 [pii].
Inman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I., et al. (2007). PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: Associations with localized stage progression. Cancer, 109(8), 1499–1505. doi:10.1002/cncr.22588.
Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., & Ueda, S. (2007). Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunology, Immunotherapy, 56(8), 1173–1182. doi:10.1007/s00262-006-0266-z.
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., et al. (2007). Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 104(9), 3360–3365. doi:10.1073/pnas.0611533104 0611533104 [pii].
Wang, W., Lau, R., Yu, D., Zhu, W., Korman, A., & Weber, J. (2009). PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. International Immunology, 21(9), 1065–1077. doi:10.1093/intimm/dxp072 dxp072 [pii].
Iwai, Y., Terawaki, S., & Honjo, T. (2005). PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. International Immunology, 17(2), 133–144. doi:10.1093/intimm/dxh194 dxh194 [pii].
Fourcade, J., Kudela, P., Sun, Z., Shen, H., Land, S. R., Lenzner, D., et al. (2009). PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. The Journal of Immunology, 182(9), 5240–5249. doi:10.4049/jimmunol.0803245 182/9/5240 [pii].
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., et al. (2010). Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 107(17), 7875–7880. doi:10.1073/pnas.1003345107 1003345107 [pii].
Marquez-Rodas, I., Cerezuela, P., Soria, A., Berrocal, A., Riso, A., Gonzalez-Cao, M., et al. (2015). Immune checkpoint inhibitors: Therapeutic advances in melanoma. Annals of Translational Medicine, 3(18), 267. doi:10.3978/j.issn.2305-5839.2015.10.27 atm-03-18-267 [pii].
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., et al. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology, 28(19), 3167–3175. doi:10.1200/JCO.2009.26.7609 JCO.2009.26.7609 [pii].
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine, 366(26), 2443–2454. doi:10.1056/NEJMoa1200690.
Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., et al. (2013). Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. Journal of Clinical Oncology, 31(34), 4311–4318. doi:10.1200/JCO.2013.51.4802 JCO.2013.51.4802 [pii].
Weber, J. S., D’Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., et al. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 16(4), 375–384. doi:10.1016/S1470-2045(15)70076-8. S1470-2045(15)70076-8 [pii].
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. New England Journal of Medicine, 372(4), 320–330. doi:10.1056/NEJMoa1412082.
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. New England Journal of Medicine, 369(2), 122–133. doi:10.1056/NEJMoa1302369.
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., et al. (2015). Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New England Journal of Medicine, 372(21), 2006–2017. doi:10.1056/NEJMoa1414428.
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., et al. (2014). Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Journal of Clinical Oncology, 32(10), 1020–1030. doi:10.1200/JCO.2013.53.0105 JCO.2013.53.0105 [pii].
Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2015). Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clinical Cancer Research,. doi:10.1158/1078-0432.CCR-15-1136 1078-0432.CCR-15-1136 [pii].
Chustecka, Z. (2015). New immunotherapy costing $1 million a year.
Eijsden, P. (2015). Fate of new cancer drug is uncertain in Netherlands, as institute deems it too costly. BMJ, 351, h6778.
Pharmacoeconomic evaluation of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adult patients who have received prior therapy. September 2011 (2011). In N. C. f. Pharmacoeconomics (Ed.). Ireland.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this chapter
Cite this chapter
Rotte, A., Bhandaru, M. (2016). Nivolumab. In: Immunotherapy of Melanoma. Springer, Cham. https://doi.org/10.1007/978-3-319-48066-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-48066-4_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-48065-7
Online ISBN: 978-3-319-48066-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)